Mary E. Wadlinger - Nov 13, 2025 Form 4 Insider Report for LAVA Therapeutics NV (LVTX)

Role
Director
Signature
/s/ Amy Garabedian, Attorney-in-Fact
Stock symbol
LVTX
Transactions as of
Nov 13, 2025
Transactions value $
$0
Form type
4
Date filed
11/17/2025, 04:30 PM
Previous filing
Feb 18, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Wadlinger Mary E. Director C/O LAVA THERAPEUTICS N.V., YALELAAN 62, UTRECHT, NETHERLANDS /s/ Amy Garabedian, Attorney-in-Fact 2025-11-17 0001814695

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LVTX Share Options (Right to Buy) Disposed to Issuer $0 -33.4K -100% $0.00 0 Nov 13, 2025 Common Shares 33.4K $0.93 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Mary E. Wadlinger is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 This option was cancelled pursuant to that certain Purchase Agreement, dated August 3, 2025, by and between the Issuer and XOMA Royalty Corporation (as amended, the "Purchase Agreement") in exchange for cash and contingent value rights ("CVRs") (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to (i) the excess of $1.04 over the per share exercise price of such option multiplied by the total number of shares underlying such in option and (ii) one CVR per share underlying such in-the-money option.